SIGA mpox therapy no longer recommended in EU

What: The European Medicines Agency (EMA) has withdrawn its conditional marketing authorization for SIGA's mpox therapy.
Why: The decision was made due to a lack of efficacy in preventing hospitalization and death in severe cases.
Signal: The EMA has received reports of adverse reactions, including serious skin and eye disorders.
Target: Healthcare providers are advised to stop prescribing SIGA's mpox therapy and switch to alternative treatments.
Risk: Patients currently taking the therapy are at risk of adverse reactions and should be closely monitored.